A40ZUB Stock Overview

Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. More details

A40ZUB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Interest payments are not well covered by earnings

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Biotest Aktiengesellschaft Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biotest
Historical stock prices
Current Share Price	€29.60
52 Week High	€0
52 Week Low	€0
Beta	0.085
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-1.33%

Recent updates

Shareholder Returns

	A40ZUB	DE Biotechs	DE Market
7D	0%	1.2%	-0.2%
1Y	n/a	-12.0%	15.6%

Return vs Industry: Insufficient data to determine how A40ZUB performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how A40ZUB performed against the German Market.

Price Volatility

Is A40ZUB's price volatile compared to industry and market?
A40ZUB volatility
A40ZUB Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.2%
Market Average Movement	6.5%
10% most volatile stocks in DE Market	12.9%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: A40ZUB's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine A40ZUB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1946	2,495	Peter Janssen	www.biotest.com

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.

Biotest Aktiengesellschaft Fundamentals Summary

How do Biotest's earnings and revenue compare to its market cap?
A40ZUB fundamental statistics
Market cap	€1.44b
Earnings (TTM)	-€24.50m
Revenue (TTM)	€635.20m

1.9x

P/S Ratio

-48.5x

P/E Ratio

Is A40ZUB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A40ZUB income statement (TTM)
Revenue	€635.20m
Cost of Revenue	€487.90m
Gross Profit	€147.30m
Other Expenses	€171.80m
Earnings	-€24.50m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 04, 2025

Earnings per share (EPS)	-0.62
Gross Margin	23.19%
Net Profit Margin	-3.86%
Debt/Equity Ratio	131.2%

How did A40ZUB perform over the long term?

See historical performance and comparison

Dividends

0.1%

Current Dividend Yield

-6%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/01 23:49
End of Day Share Price	2025/05/29 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biotest Aktiengesellschaft is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Volker Braun	Commerzbank AG
Martin Possienke	GSN North America
Torben Teichler	Hauck Aufhäuser Investment Banking

Biotest DB:A40ZUB Stock Report